California is currently home to 5591 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
Recruiting
The investigator is examining the safety of transplanting cells, that have been engineered to produce a growth factor, into the motor cortex (brain) of patients with Amyotrophic Lateral Sclerosis (ALS). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neural cell. The growth factor is called glial cell line-derived... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Amyotrophic Lateral Sclerosis
MS-ResearchBiomarkerS
Recruiting
This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and/or spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging
RB Liquid Biopsy Biorepository
Recruiting
Retinoblastoma (RB) is a primary eye cancer that forms in the back of the eye of infants and toddlers. Traditionally, RB is diagnosed without a biopsy; tumor can only be studied once an eye has been surgically removed. Given this limitation, we use aqueous humor (AH), the clear fluid in the front of the eye to detect specific markers, or information, that comes from the tumor itself.
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
02/05/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Retinoblastoma, Retinoblastoma Bilateral, Retinoblastoma Unilateral
Treatment of Refractory Infantile Spasms With Fenfluramine
Recruiting
This is a phase II clinical trial in which children with refractory infantile spasms (also called epileptic spasms or West syndrome) will be treated with fenfluramine, to evaluate efficacy, safety, and tolerability. Patients with infantile spasms that have not responded to treatment with vigabatrin and ACTH we will be invited to participate. Study participants will undergo baseline video-EEG, receive treatment with fenfluramine for 21 days, and then undergo repeat video-EEG to determine effectiv... Read More
Gender:
ALL
Ages:
Between 12 months and 36 months
Trial Updated:
02/05/2024
Locations: UCLA Health, Los Angeles, California
Conditions: Infantile Spasm
CNS10-NPC for the Treatment of RP
Recruiting
The investigator is examining the safety of transplanting cells into the subretinal space of patients with Retinitis Pigmentosa (RP). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neuronal cell. The cells are called "CNS10-NPC." The investigational treatment has been tested in animals, but it has not yet been tes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Retina-Vitreous Associates Medical Group, Beverly Hills, California
Conditions: Retinitis Pigmentosa
Microdosing ICG for Serial Colonic Perfusion Study During Surgery
Recruiting
using microdosing of ICG vs regular dosing of ICG for perfusion assessment during surgery
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/03/2024
Locations: UC San Diego, La Jolla, California
Conditions: Perfusion; Complications
HEPA, PM2.5, and Cardiometabolic Health
Recruiting
The goal of this randomized, double-blind, crossover trial is to test the hypothesis that a longer-term indoor HEPA filtration intervention can improve cardiometabolic profiles by reducing indoor PM2.5 exposures in at-risk individuals.
Gender:
ALL
Ages:
Between 65 years and 84 years
Trial Updated:
02/01/2024
Locations: Keck School of Medicine, University of Southern California, Los Angeles, California
Conditions: Air Pollution, Cardiometabolic Health
Epidemiology of Young Lung Cancer - Survey
Recruiting
This is a 100% virtual (remote), case-case study to explore potential environmental, lifestyle and genetic factors that may be associated with driver mutations of young lung cancer in the U.S.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: USC Keck School of Medicine, Los Angeles, California
Conditions: NSCLC
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Recruiting
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: UCLA Health Westwood Cancer Care, Los Angeles, California
Conditions: Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
STAT: Standard Therapy Plus Active Therapy
Recruiting
The objective of the study is to assess the efficacy of STAT, an activity-based therapy protocol compared to standard therapy (ST) to improve functional outcome and reduce disability in patients recovering from burn injury. This randomized multi-center trial is designed with two parallel treatment groups: STAT and ST. Efficacy of the STAT protocol will be determined through comparison to the ST only group. It will be conducted at seven burn centers.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/31/2024
Locations: University of California Davis Medical Center-Regional Burn Center, Sacramento, California
Conditions: Burn Injury, Physical Injury, Thermal Burn
The Acute Burn ResUscitation Multicenter Prospective Trial
Recruiting
This is a prospective randomized multi-center study which will compare acute fluid resuscitation using a colloid strategy (LR + 5% Albumin) to a crystalloid strategy (LR alone), in adults with an acute burn involving at least 25% of their total body surface area.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: University of California Davis, Regional Burn Center, Sacramento, California
Conditions: Burn Injury
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Recruiting
Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of Universal Chimeric Antigen Receptor T-cells targeting CD123 (UCART123v1.2) and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/31/2024
Locations: University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Conditions: Relapsed/Refractory Acute Myeloid Leukemia